Online inquiry

IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7958MR)

This product GTTS-WQ7958MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL7R gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002185.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3575
UniProt ID P16871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7958MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8695MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ13466MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ8571MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ7543MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ1321MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-700
GTTS-WQ2601MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 531
GTTS-WQ14874MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ7365MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FZD8-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW